RecruitingNot ApplicableNCT06507930
The COMPASSION Study
The COMPASSION Study: Applying Telehealth to Innovate and Strengthen Connections for Patients With Metastatic Breast Cancer Receiving Hospice Care
Sponsor
Dana-Farber Cancer Institute
Enrollment
200 participants
Start Date
Sep 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- Patient of any gender with unresectable locally advanced or metastatic breast cancer
- Eligible for in-home hospice services and referred by DFCI clinical team to in-home hospice \</= 1 week before enrollment
- Ability to conduct video or phone check-ins, even if assistance required.
- Able to provide verbal consent with a willingness to take a survey at 4-6 weeks, if medically able
- Hospice setting is within Massachusetts
- Non-English language allowed but interpreter services must be present at each meeting and will be coordinated by scheduling team
- Willingness to provide a caregiver/loved one's contact information for survey contact at 4 weeks after enrollment
Exclusion Criteria4
- Unable to provide verbal consent
- Hospice care planned outside of a home setting (note: if participants start out in a home hospice setting but later transition their hospice care to an inpatient setting, enrollment is allowed as long as they started in a home setting)
- Hospice setting outside of Massachusetts
- Individuals who are under the age of 18, as this is not a project focused on pediatric patients.
Interventions
OTHERTelehealth Hospice Visits
Telehealth check-in appointments with oncology care team, MD, PA, NP, or hospice nurse, via HIPAA compliant telehealth platform, Zoom, or by phone call.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06507930
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892139 locations
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT066493311 location
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT0699384410 locations